Introduction
============

Each year, over 25 000 people in England die from venous thromboembolism developed in hospital.[@ref1] This number is more than the combined total of deaths from breast cancer, AIDS, and traffic accidents, and more than 25 times the number of deaths from meticillin resistant *Staphylococcus aureus*.[@ref1] Venous thromboembolism is an important and preventable cause of morbidity and mortality,[@ref2] with almost a third of survivors experiencing long term effects.[@ref3] [@ref4] To improve survival and to prevent complications, the occurrence of venous thromboembolism needs to be reduced.[@ref5]

Independent risk factors for venous thromboembolism have been identified[@ref6] [@ref7] [@ref8] and prophylaxis exists for high risk individuals.[@ref9] In 2010, the UK National Institute for Health and Clinical Excellence (NICE) issued new guidance to improve the prevention of venous thromboembolism for patients by use of cost effective interventions.[@ref10] The guidance highlighted the need for new research to develop and validate risk prediction models to predict absolute risk of venous thromboembolism, taking account of patient factors, comorbidity, and concurrent medication, and incorporating venous thromboembolism events arising in a community setting.[@ref10] It recommended the development of new risk prediction models by use of primary care research databases.[@ref10] Such databases, with linked cause of death data, contain robust information on many of the relevant exposures and outcomes.[@ref11] They are also represent the populations where such a model is likely to be used to inform treatment decisions, including the use of prophylaxis[@ref10] and the use of medication which might increase venous thromboembolism risk.

Once validated, suitable clinical risk prediction models can be integrated into clinical computer systems to help systematically identify individuals at high risk of venous thromboembolism and to alert clinicians to those who might benefit from interventions.[@ref12] [@ref13] Although there are currently no validated algorithms to predict risk for venous thromboembolism designed for use in primary care, computerised clinical decision support could improve appropriate use of thromboprophylaxis in a hospital setting.[@ref14]

We developed and validated a risk prediction algorithm (QThrombosis) to estimate the individual absolute risk of venous thromboembolism to target prophylaxis to the people most likely to benefit.[@ref10] [@ref15] The algorithm could also be used to inform treatment decisions regarding use of medication that may increase risk of venous thromboembolism, such as the combined oral contraceptive pill,[@ref7] [@ref8] [@ref16] [@ref17] [@ref18] [@ref11] hormone replacement therapy,[@ref7] [@ref8] [@ref19] [@ref20] [@ref21] and antipsychotic medication.[@ref8] We developed the algorithm to estimate the risk of individuals developing venous thromboembolism up to five years into the future, rather than the current risk of having venous thromboembolism in patients presenting with symptoms such as swollen legs.

Methods
=======

Study design and data source
----------------------------

We did a prospective open cohort study in a large population of primary care patients using the QResearch database (version 29). We included all general practices in England and Wales that had been using their computer systems with Egton Medical Information Systems (EMIS) for at least a year. We randomly allocated two thirds of practices to a derivation dataset and the remaining third to a validation dataset using the random number utility in Stata.

We identified an open cohort of patients aged 25-84 years drawn from patients registered with general practices between 1 January 2004 and 30 April 2010. We excluded patients who did not have a postcode related Townsend score, patients with a history of venous thromboembolism, and those who had been prescribed oral anticoagulation drugs at any time before the study start date. We also excluded women with recorded evidence of pregnancy in the preceding 12 months, because the risk of venous thromboembolism in pregnancy is likely to require separate analysis using data where gestation, mode, and date of delivery dates are well recorded. Entry to the cohort was the latest of two dates: the study start date (1 January 2004) or 12 months after the patient registered with the practice. We censored patients at the earliest date of a diagnosis of venous thromboembolism, death, deregistration with the practice, last upload of computerised data, five years after study entry, or the study end date (30 April 2010).

Clinical outcomes
-----------------

Our clinical outcome was incident diagnosis of venous thromboembolism including either deep vein thrombosis or pulmonary embolism, recorded either on the patients' general practice record using the relevant Read diagnostic codes or on their linked Office of National Statistics cause of death record using the relevant International Classification of Diseases (ICD)-9 codes or ICD-10 diagnostic codes. We used codes similar to those used in previous studies where possible.[@ref16]

Risk factors
------------

We examined predictor variables based on established risk factors for venous thromboembolism, focusing on those that are likely to be recorded in the patient's electronic record and that the patient is likely to know (box 1).

### Box 1 Predictor variables based on established risk factors for venous thromboembolism

-   Age[@ref7] [@ref8] (continuous)

-   Body mass index[@ref7] [@ref8] [@ref11] [@ref22] (continuous)

-   Smoking status[@ref7] [@ref8] [@ref22] [@ref11] (non-smoker; ex-smoker; light, moderate, or heavy smoker)

-   Townsend deprivation score[@ref7] [@ref8] (continuous)

-   Varicose veins[@ref6] [@ref8] (yes/no)

-   Congestive cardiac failure[@ref8] [@ref23] [@ref24] [@ref25] (yes/no)

-   Rheumatoid arthritis[@ref7] [@ref24] (yes/no)

-   Chronic renal disease[@ref7] [@ref8] (yes/no)

-   Inflammatory bowel disease[@ref8] [@ref24] [@ref26] [@ref27] (yes/no)

-   Cancer[@ref6] [@ref7] [@ref8] [@ref23] [@ref28] (lung, gastrointestinal, pancreas, renal, breast, prostate, other)

-   Recent hospital admission[@ref6] [@ref8] (yes/no)

-   Recent hip fracture or hip surgery (or both)[@ref8] (yes/no)

-   Current use of antipsychotic drugs[@ref7] [@ref8] (none, atypical, typical)

-   Current use of tamoxifen[@ref8] [@ref28] (yes/no)

-   Current use of hormone replacement therapy[@ref7] [@ref8] [@ref19] [@ref20] [@ref21] (none, equine or non-equine hormone replacement therapy)

-   Use of antiplatelets (yes/no)

-   Cardiovascular disease[@ref6] [@ref7] [@ref8] (stroke, transient ischaemic attack, or coronary heart disease)

-   Atrial fibrillation (yes/no)

-   Asthma[@ref7] [@ref8] (yes/no)

-   Chronic obstructive pulmonary disease[@ref7] [@ref8] (yes/no)

-   Family history of venous thromboembolism[@ref29] (yes/no)

We defined recent events as events recorded in the 12 months before study entry, and we categorised them as: within the past 6 months, 6-12 months ago, or not in the past 12 months. We defined current medication use as at least one prescription in the 30 days preceding study entry for antipsychotic drugs and tamoxifen, since most prescriptions are issued monthly. We defined current use of oral contraceptives and hormone replacement therapy as at least one prescription in the past six months, since most prescriptions are issued for this period.

Derivation and validation of the models
---------------------------------------

We developed and validated the risk prediction algorithm using established methods.[@ref10] [@ref12] [@ref30] [@ref31] [@ref32] [@ref33] We used multiple imputation to replace missing values for body mass index and smoking status, and used these values in our main analyses.[@ref34] [@ref35] [@ref36] [@ref37] We carried out five imputations. We used Cox proportional hazards models to estimate the coefficients for risk factors for men and women separately, using robust variance estimates to allow for the clustering of patients within general practices. We used Rubin's rules to combine the results across the imputed datasets.[@ref38] We used fractional polynomials to model non-linear risk relations with continuous variables.[@ref39] We fitted a full model initially and retained variables if they had a hazard ratio of more than 0.80 or less than 1.20 (for binary variables) and were significant at the 0.01 level. To simplify the model, we then focused on variables for the most common conditions and medications and combined similar variables with comparable hazard ratios where possible. We compared Akaike information criteria for models with and without Townsend score to determine the score's contribution.

We examined interactions between predictor variables and age. We used the regression coefficients for each variable from the final model as weights, which we combined with the baseline survivor function evaluated for each year up to five years to derive risk equations at each year of follow up.[@ref40] We estimated the baseline survivor function based on zero values of centred continuous variables, with all binary predictor values set to zero, using the methods implemented in Stata.

We used multiple imputation in the validation cohort to replace missing values for body mass index and smoking. We then applied the risk equations for men and women obtained from the derivation cohort to the validation cohort and calculated measures of discrimination. We calculated the R^2^ statistic[@ref41] (estimated variation in time to venous thromboembolism), the D statistic[@ref42] (a measure of discrimination where higher values indicate better discrimination), and the area under the receiver operating characteristic curve (receiver operating curve statistic) at one and five years. We assessed calibration (comparing the mean predicted risks at one and five years with the observed risk by tenth of predicted risk. We obtained the observed risk by using the Kaplan-Meier estimate evaluated at one and five years.

We applied the algorithm to the validation cohort to define the thresholds for the 0.5%, 1%, 5%, and 10% of patients at highest estimated risk of venous thromboembolism at one and five years. We used all the available data on the database to maximise the power and generalisability of the results. We used Stata (version 11) for all analyses.

Results
=======

Overall study population
------------------------

Overall, 564 QResearch practices in England and Wales met our inclusion criteria, of which 375 were randomly assigned to the derivation dataset with the remainder assigned to a validation cohort. We identified 2 598 829 patients aged 25-84 years in the derivation cohort. We excluded 152 719 (5.9%) patients without a recorded Townsend score, 26 211 (1.0%) on oral anticoagulation treatment, 85  306 (3.3%) with evidence of pregnancy in the preceding 12 months, 168 (0.01%) with a missing date for venous thromboembolism, and 19 724 (0.8%) with a history of venous thromboembolism. These exclusions left 2  314  701 patients for analysis.

We identified 1 354 517 patients aged 25-84 years in the validation cohort. We excluded 44 973 (3.3%) patients without a recorded Townsend score, 13 815 (1.0%) on oral anticoagulation, 44 318 (3.3%) with evidence of pregnancy in the preceding 12 months, 113 with a missing date for venous thromboembolism, and 10 696 (0.6%) with a history of venous thromboembolism. These exclusions left 1 240 602 patients for analysis.

The baseline characteristics of each cohort were similar (table 1[](#tbl1){ref-type="table"}). As in previous studies,[@ref12] [@ref13] [@ref30] the patterns of missing data supported the use of multiple imputation to replace missing values for smoking and body mass index (not shown, available from the authors).

###### 

 Baseline characteristics of patients in derivation and validation cohorts

  --------------------------------------------------------------------------------------------
                                                     Derivation cohort\   Validation cohort\
                                                     (n=2 314 701)        (n=1 240 602)
  -------------------------------------------------- -------------------- --------------------
  Male                                               1 190 500 (51.4)     637 482 (51.4)

  Female                                             1 124 201 (48.6)     603 120 (48.6)

  Mean age (SD)                                      47.6 (15.7)          47.7 (15.7)

  Mean Townsend score (SD)                           −0.1 (3.5)           −0.1 (3.5)

  BMI recorded                                       1 828 253 (79.0)     975 051 (78.6)

  Mean BMI (SD)                                      26.4 (4.8)           26.4 (4.8)

  Smoking status recorded                            2 168 137 (93.7)     1 160 241 (93.5)

  BMI and smoking status recorded                    1 818 859 (78.6)     970 083 (78.2)

  **Smoking status**                                                      

  Non-smoker                                         1 187 610 (51.3)     634 966 (51.2)

  Ex-smoker                                          430 425 (18.6)       231 139 (18.6)

  Smoking amount not recorded                        64 622 (2.8)         42 591 (3.4)

  Light smoker (\<10 cigarettes/day)                 168 021 (7.3)        82 943 (6.7)

  Moderate smoker (10-19 cigarettes/day)             189 805 (8.2)        98 492 (7.9)

  Heavy smoker (≥20 cigarettes/day)                  127 654 (5.5)        70 110 (5.7)

  **Medical and family history**                                          

  Family history of venous thromboembolism           67 (0.0)             27 (0.0)

  Varicose veins                                     41 054 (1.8)         21 737 (1.8)

  Congestive cardiac failure                         15 081 (0.7)         7910 (0.6)

  Rheumatoid arthritis                               16 601 (0.7)         8918 (0.7)

  Chronic renal disease                              5957 (0.3)           3275 (0.3)

  Inflammatory bowel disease                         14 910 (0.6)         7761 (0.6)

  Lung cancer                                        1526 (0.1)           723 (0.1)

  Gastrointestinal cancer                            7633 (0.3)           3981 (0.3)

  Pancreatic cancer                                  197 (0.0)            104 (0.0)

  Renal cancer                                       3209 (0.1)           1685 (0.1)

  Breast cancer (women only)                         14 004 (0.6)         7399 (0.6)

  Prostate cancer (men only)                         6326 (0.3)           3326 (0.3)

  Other cancers                                      18 316 (0.8)         9582 (0.8)

  Current typical antipsychotic drugs                51 343 (2.2)         28 471 (2.3)

  Current atypical antipsychotic drugs               13 031 (0.6)         6841 (0.6)

  Current oral contraceptives (women only)           98 690 (4.3)         53 654 (4.3)

  Current hormone replacement therapy (women only)   52 218 (2.3)         28 291 (2.3)

  Current tamoxifen (women only)                     7116 (0.3)           3849 (0.3)

  Hip fracture or replacement in past 182 days       2777 (0.1)           1318 (0.1)

  Hospital admission in past 182 days                27 657 (1.2)         16 106 (1.3)
  --------------------------------------------------------------------------------------------

BMI=body mass index. Figures in the tables are number (%) unless otherwise specified.

Rates of incident venous thromboembolism
----------------------------------------

In the derivation cohort, we identified 14  756 incident cases of venous thromboembolism arising from 10 095 199 person years of observation, giving a rate of 14.6 per 10 000 person years. Of these 14 756 cases, 5799 (39.3%) were pulmonary embolism and 8957 (60.7%) were deep vein thrombosis. We identified 14 039 (95.1%) cases of venous thromboembolism from general practice records and 717 (4.9%) solely from linked Office of National Statistics death records.

In the validation cohort, we identified 6913 incident cases of venous thromboembolism arising from 4 632 694 person years of observation, giving a rate of 14.9 per 10 000 person years. Of these 6913 cases, we identified 6526 (94.4%) from general practice records and 387 (5.6%) solely from linked Office of National Statistics death records.

Predictor variables
-------------------

After fitting a full model, we combined variables that were similar with comparable hazard ratios where possible. For example, we combined the various types of cancer into one variable (any cancer) since the hazard ratios for the individual types of cancer were similar and the 95% confidence intervals overlapped. Similarly, we combined the variables for current use of typical and atypical antipsychotic drugs into one variable and equine and non-equine hormone replacement therapy into another variable. For example, the adjusted hazard ratio for women was 1.27 (95% confidence interval 1.16 to 1.40) for typical antipsychotic drugs and 1.69 (1.36 to 2.11) for atypical antipsychotic drugs. The adjusted hazard ratio for both types of antipsychotic drugs combined was 1.55 (1.32 to 1.81). We also combined two variables for hip fracture or operation and recent hospital admission.

Table 2[](#tbl2){ref-type="table"} shows the predictor variables selected for the final simplified models for men and women. We found no significant interaction terms with age.

###### 

 Adjusted hazard ratios (95% CI) for final models in derivation cohort

                                          Women                         Men                                        
  --------------------------------------- ------- --------------------- --------- -- ------ ---------------------- ---------
  **Smoking status**                                                                                               
  Non-smoker                              4533    1.00                  --           3148   1.00                   --
  Ex-smoker                               1689    1.07 (1.01 to 1.15)   0.030        2238   1.06 (0.995 to 1.13)   0.070
  Light smoker                            443     1.22 (1.09 to 1.37)   0.001        618    1.22 (1.09 to 1.35)    \<0.001
  Moderate smoker                         558     1.17 (1.05 to 1.29)   0.003        592    1.37 (1.22 to 1.52)    \<0.001
  Heavy smoker                            375     1.34 (1.18 to 1.52)   \<0.001      562    1.49 (1.33 to 1.66)    \<0.001
  **Medical history**                                                                                              
  Varicose veins                          407     1.40 (1.24 to 1.58)   \<0.001      172    1.38 (1.18 to 1.63)    \<0.001
  Congestive cardiac failure              206     1.40 (1.2 to 1.62)    \<0.001      168    1.33 (1.13 to 1.57)    0.001
  Chronic renal disease                   46      1.60 (1.17 to 2.19)   0.003        62     1.92 (1.50 to 2.44)    \<0.001
  Any cancer                              573     1.85 (1.69 to 2.03)   \<0.001      505    2.18 (1.97 to 2.41)    \<0.001
  Chronic obstructive airways disease     360     1.41 (1.24 to 1.62)   \<0.001      429    1.62 (1.45 to 1.80)    \<0.001
  Inflammatory bowel disease              87      1.45 (1.15 to 1.82)   0.002        94     1.5 (1.18 to 1.91)     0.001
  Hospital admission in past six months   244     1.86 (1.63 to 2.14)   \<0.001      209    1.93 (1.64 to 2.27)    \<0.001
  **Current medication**                                                                                           
  Antipsychotic drugs†                    187     1.55 (1.32 to 1.81)   \<0.001      121    1.84 (1.51 to 2.23)    \<0.001
  Tamoxifen†                              97      1.48 (1.19 to 1.84)   \<0.001      NA     NA                     NA
  Oral contraceptives†                    229     1.33 (1.12 to 1.58)   0.001        NA     NA                     NA
  Hormone replacement therapy†            447     1.20 (1.08 to 1.34)   0.001        NA     NA                     NA

95% CI=95% confidence intervals. NA=not applicable. \*Hazard ratios adjusted for all other terms in the table, age, and body mass index (BMI). Models included fractional polynomial terms for age and BMI. For women, terms were age^−0.5^, ln(age), BMI^−2^, BMI^−2^ln(BMI). For men, terms were age^3^, age^3^ln(age), BMI^−2^, BMI^−2^ln(BMI). †Compared with patients without this characteristic.

The risk of venous thromboembolism in women was linked to increasing age, body mass index, and quantity of cigarettes smoked every day. Risks were also raised in women with varicose veins (40% increase), congestive cardiac failure (40%), chronic renal disease (60%), any cancer (85%), chronic obstructive airways disease (41%), inflammatory bowel disease (45%), and those admitted to hospital in the past six months (86%).

The risk of venous thromboembolism increased in women prescribed antipsychotic drugs, (55% increase), oral contraceptives (33%), hormone replacement therapy (20%), and tamoxifen (48%). Although the risk of venous thromboembolism rose with increasing levels of deprivation, the effect was not marked and did not substantially affect the model fit. Therefore, we did not include deprivation in the final model.

Our final model for men included similar variables except for those variables specific to women (hormone replacement therapy, oral contraceptives, and tamoxifen). The magnitudes of the adjusted hazard ratios were generally similar to those found for women.

In our multivariate analysis, we found no significant change in risk in men or women for: current antiplatelet therapy, atrial fibrillation, cardiovascular disease, asthma, or family history of venous thromboembolism (although the number of patients with family history of venous thromboembolism recorded was very low).

Validation
----------

### Discrimination

The validation statistics (table 3[](#tbl3){ref-type="table"}) showed that the risk prediction algorithm explained 33% of the variation in time to venous thromboembolism for women and 34% for men in the validation cohort when evaluated over five years. At five years, the D statistic was 1.43 for women and 1.45 for men. The receiver operating curve statistic was 0.75 in both sexes. The performance of the algorithm over five years was marginally better than the performance over one year (table 3).

###### 

 Validation statistics for risk prediction algorithm in validation cohort

                         Mean (95% CI) evaluated at one year   Mean (95% CI) evaluated at five years
  ---------------------- ------------------------------------- ---------------------------------------
  **Women**                                                    
  R^2^ statistic (%)\*   28.02 (24.60 to 31.44)                32.78 (31.08 to 34.48)
  D statistic†           1.28 (1.17 to 1.39)                   1.43 (1.37 to 1.49)
  ROC statistic†         0.71 (0.70 to 0.73)                   0.75 (0.74 to 0.76)
  **Men**                                                      
  R^2^ statistic (%)     31.11 (27.57 to 34.64)                33.51 (31.71 to 35.30)
  D statistic            1.38 (1.26 to 1.49)                   1.45 (1.39 to 1.51)
  ROC statistic          0.72 (0.70 to 0.74)                   0.75 (0.74 to 0.76)

\*Statistic shows explained variation (higher values indicate that more variation is explained). †ROC=receiver operating curve. ROC statistic is a measure of discrimination (higher values indicate better discrimination).

Calibration
-----------

The figure[](#fig1){ref-type="fig"} compares the mean predicted risks with the observed risks at one and five years, by tenths of the distribution of predicted risk, to assess the calibration of the model in the validation cohort. We found a close similarity between the mean predicted risks and the observed risks at one and five years within every tenth of predicted risk, indicating that the algorithm was well calibrated. For example, in the top tenth of predicted risk for women, the mean predicted five year risk was 2.78% and the observed risk was 2.70%, giving a ratio of 1.03. For men, the corresponding figures were 2.46% and 2.35% , giving a ratio of 1.05.

![Mean predicted risks and observed risks of venous thromboembolism by tenth of predicted risk, applying risk prediction scores to the validation cohort](hipj838102.f1_default){#fig1}

Thresholds and risk stratification
----------------------------------

Since the QThrombosis algorithm is new (box 2), we had no established thresholds for defining a high risk group. Therefore, we calculated cut-offs to define the top 0.5%, 1%, 5%, and 10% for absolute risk of venous thromboembolism based on the estimated risks at one and five years in the validation cohort (men and women combined).

Table 4[](#tbl4){ref-type="table"} shows the cut-offs, and the total number of patients that would fall into each group based on the one and five year risk. It also shows the total number of incident cases of venous thromboembolism occurring in the groups and the overall total number of cases of venous thromboembolism. For example, the 90th centile defined a high risk group with a five year risk score of more than 15 per 1000. There were 2441 new cases of venous thromboembolism within this group over five years, which accounted for 35% of all new cases of venous thromboembolism. In other words, the sensitivity was 35% for this cut-off. The positive predictive value at this cut-off was 2%. The 99th centile defined a high risk group with a five year risk score of more than 38 per 1000. There were 350 new cases of venous thromboembolism in this group over five years. The sensitivity based on the 99th centile was 5% and the positive predictive value was 2.8%.

###### 

  Incident cases of venous thromboembolism in groups of predicted risk within one and five years, in validation cohort (men and women combined)

                        Risk threshold per 1000   No of patients in risk group   No of patients in risk group with new VTE diagnosis   Total no of new VTE diagnoses   Sensitivity (%)   Positive predictive value (%)
  --------------------- ------------------------- ------------------------------ ----------------------------------------------------- ------------------------------- ----------------- -------------------------------
  **Five year risk**                                                                                                                                                                     
  Top 10% risk score    15                        124 060                        2441                                                  6913                            35.3              2.0
  Top 5% risk score     21                        62 027                         1400                                                  6913                            20.3              2.3
  Top 1% risk score     38                        12 405                         350                                                   6913                            5.1               2.8
  Top 0.5% risk score   48                        6203                           191                                                   6913                            2.8               3.1
  **One year risk**                                                                                                                                                                      
  Top 10% risk score    3                         124 042                        595                                                   1686                            35.3              0.5
  Top 5% risk score     4                         62 018                         356                                                   1686                            21.1              0.6
  Top 1% risk score     7                         12 406                         101                                                   1686                            6.0               0.8
  Top 0.5% risk score   9                         6202                           57                                                    1686                            3.4               0.9

VTE=venous thromboembolism.

### Box 2 QThrombosis web calculator

1.  A simple web calculator implements the QThrombosis algorithm and is publicly available. It also has the open source software for download ([www.qthrombosis.org](http://www.qthrombosis.org/))

Clinical example 1
------------------

A 39 year old woman, who is a heavy smoker, has a body mass index of 36.7 and a history of varicose veins, and is currently taking the oral contraceptive pill. She has a one year thrombosis risk of 0.2% and a five year risk of 1.1%. A similar woman not currently prescribed the oral contraceptive pill has a one year risk of 0.15% and a five year risk of 0.9%.

Clinical example 2
------------------

A 54 year old woman, who is a moderate smoker, has a body mass index of 36.7, a history of varicose veins, and chronic obstructive airways disease. She has been admitted to hospital in the past six months, and is currently prescribed hormone replacement therapy. She has a one year thrombosis risk of 0.8% and a five year risk of 4.5%. A similar woman not currently prescribed hormone replacement therapy has a one year risk of 0.7% and a five year risk of 3.8%.

Clinical example 3
------------------

A 78 year old man, who is a heavy smoker, has a body mass index of 29.4, chronic obstructive airways disease, chronic renal disease, and congestive cardiac failure, and is currently prescribed an antipsychotic drug. He has a one year thrombosis risk of 4.2% and a five year risk of 20.7%. A similar man not currently prescribed antipsychotic drugs has a one year risk of 2.3% and a five year risk of 11.8%.

Clinical example 4
------------------

An 80 year old woman, who is an ex-smoker, has a body mass index of 27.6, congestive cardiac failure, chronic renal disease, and breast cancer. She has been admitted to hospital in the past six months and is currently prescribed tamoxifen and an antipsychotic drug. She has a one year thrombosis risk of 7.1% and a five year risk of 33.5%. A similar woman not prescribed tamoxifen or antipsychotic drugs has a one year risk of 3.2% and a five year risk of 16.4%.

Discussion
==========

Venous thromboembolism is a common, lethal condition which can be prevented with the appropriate use of effective interventions in high risk individuals.[@ref10] We have developed and validated a new risk prediction algorithm designed to predict the absolute risk of venous thromboembolism in a large representative primary care population. This algorithm could be used to identify patients at highest risk of venous thromboembolism and those most likely to benefit from intervention, such as change in medication, mechanical prophylaxis, or thromboprophylactic medication. The algorithm is not, however, designed to assess the current risk of venous thromboembolism---for example, in a symptomatic patient presenting with a swollen leg. We think our study provides new information which helps address gaps in evidence highlighted by recent NICE guidance.[@ref10]

Although our study has focused on the formal development and validation of the algorithm, we can see several clinical situations where the algorithm embedded in a clinical risk calculator might be useful. Firstly, it could be used to identify patients at increased risk of venous thromboembolism on or before hospital admission or before long haul flights, so that prophylaxis can be considered in a more systematic way.[@ref10]

Secondly, the algorithm could be used when considering medication which might increase venous thromboembolism risk, such as the oral contraceptive pill, tamoxifen, hormone replacement therapy, or antipsychotic drugs. For example, a woman might be interested to know her absolute level of risk and how it might change with medication, and this risk can be assessed against the expected benefits of the medication.

Thirdly, the algorithm could be used to identify high risk groups of patients suitable for further testing, closer monitoring, or preventative treatment. Pragmatic randomised trials can establish the true benefits of preventive treatment in individuals at high risk of thromboembolic events and the exact cut-offs for treatment where the benefits will outweigh the risks. We have presented clinical examples of estimated absolute risk at one and five years although the algorithm can calculate risks at 1, 2, 3, 4, or 5 years; therefore, relevant risks can be calculated depending on the clinical situation and intervention being considered.

Other studies of risk models
----------------------------

While other studies have examined risk factors for venous thromboembolism, studies specifically designed to develop and validate risk prediction algorithms for venous thromboembolism are lacking. We identified only one cohort study which developed a risk prediction score for venous thromboembolism over a 10 year observation period starting in 1993. Heinemann and colleagues reported the Bavarian thromboembolic risk which examined venous thromboembolism risk in 4337 young women (18-55 years) using genetic information and self reported outcomes via a questionnaire followed up by a telephone interview.[@ref43] The sample was limited by size since it included only 34 cases of venous thromboembolism. However, it was the first such study and included a careful analysis of many candidate variables including age, body mass index, varicose veins, use of hormone replacement therapy, family history of cardiovascular disease, oral contraceptive use, smoking status, educational attainment, reproductive history, and laboratory measurements, but no acute events such as surgery or immobilisation. Most of these variables were not,important and did not improve prediction, or were considered impractical to use. Hence, their final model included only three variables (age, body mass index, and family history) in addition to genetic information. While the Bavarian thromboembolic risk algorithm was not published or validated, their analysis and commentary did support the use of such an algorithm for future risk stratification. The study also concluded that the algorithm could be based on clinical data alone at least until better genetic information is more available.[@ref43]

More recently, a predictive model for chemotherapy associated thrombosis has been developed in 2701 patients with selected cancers undergoing chemotherapy in a hospital outpatient setting followed up over a median of 2.5 months.[@ref44] The algorithm was based on five predictive variables: site of cancer, body mass index, use of erythropoiesis stimulating agent, haemoglobin more than 100g/L, and leucocyte count of more than 11×10^9^/L. The same team validated the predictive model in 1365 patients from the same study[@ref44] with a C statistic of 0.7 (which is lower than the receiver operative curve value of 0.75 from our present study). Our study is more suitable for use in a general primary care population.

Strengths
---------

The strengths and weaknesses of general practice databases for the development and validation of clinical risk prediction algorithms have been described in detail elsewhere.[@ref12] [@ref32] In summary, key strengths include size; duration of follow-up; representativeness; and lack of selection, recall, and respondent bias. UK general practices have good levels of accuracy and completeness in recording clinical diagnoses and prescribed medications,[@ref45] [@ref46]

We think our study has good face validity since it has been undertaken in the setting where most patients in the UK are assessed, treated, and followed up. Our study also includes established exposures known to increase risk of venous thromboembolism. We have been able to include a long list of predictor variables and establish which factors remain independent after adjustment and their relative importance. The strength of the association between cancer and risk of venous thromboembolism is similar to that reported elsewhere.[@ref28] The size of our study is particularly important since venous thromboembolism is uncommon in certain population groups.

We have also developed the algorithm in one cohort and validated it in a separate cohort that represents the patients likely to be considered for preventative measures. Although the validation cohort is derived from general practices using the same clinical computer system (EMIS), they were physically discrete. Also, since this computer system is used in over half of UK general practices, our results are likely to generalise well. A separate independent validation study using another general practice database is planned (to be undertaken by another independent team).

Limitations
-----------

Limitations included lack of formally adjudicated outcomes, information bias, potential for missing data, and residual confounding. Our database has linked cause of death from the UK Office of National Statistics, and our study is therefore likely to have picked up most cases of venous thromboembolism thereby minimising ascertainment bias. Patients who die from venous thromboembolism in hospital will have the cause of death recorded on their death certificate and therefore will be included on the linked cause of death data. Other patients who have been diagnosed with but do not die from venous thromboembolism in hospital will have the information recorded in hospital discharge letters which are sent to the general practitioner and then entered into the patient's electronic record.

The recorded clinical diagnoses of venous thromboembolism were not independently verified for the study, but in other studies the inclusion of possible venous thromboembolism cases gave similar adjusted odds ratios to that based on confirmed cases.[@ref11] The observed incidence rate in our population was close to the 11.7 per 10  000 person years reported elsewhere[@ref47] and in line with the estimated 5-10 per 10 000 person years for women of reproductive age.[@ref48] Although we are reliant on the accuracy of information recorded by primary care physicians, we think that the quality of information is likely to be good since previous studies have validated similar outcomes and exposures using questionnaire data and found levels of completeness and accuracy to be high.[@ref11]

Although genes associated with increased risk of venous thromboembolism have been identified,[@ref49] such information is not routinely collected or recorded in electronic records and hence we were unable to include genetic information in our analysis. We concluded that although the absence of genetic information may be a limitation of our study, it is unlikely to have a major effect on the use of the QThrombosis algorithm, because such information is unlikely to be available for use in a general risk calculator.

We designed this study to identify patients at high risk of venous thromboembolism who might require prophylaxis before a hospital procedure or other event rather than to help diagnose it in symptomatic patients. Similarly, our study was not designed to estimate how the risk of thromboembolism might change during the course of a hospital episode. Further analysis of this kind might be possible once the QResearch database is linked to secondary care data.

Furthermore, our findings cannot offer hypotheses on individual mechanisms in the genesis of thromboembolism for comorbid conditions or individual drugs. For some clinical conditions (such as cancer), biological mechanisms have already been proposed.[@ref50] Even in a dataset of this size, the number of patients exposed to some individual drugs is too small to estimate separate hazard ratios. We cannot rule out the possibility of residual confounding by indication, which is a further barrier to making definitive risk comparisons between individual drugs. However, in terms of our overall findings, the direction and the magnitude of the hazard ratios associated with risk of venous thromboembolism are broadly in line with those reported elsewhere,[@ref29] with largest effects seen in association with cancer,[@ref28] recent hip fracture, hip surgery, and hospital admission.[@ref15] Family history was not associated with risk of venous thromboembolism, yet this finding is likely to reflect the small numbers of patients with this information recorded.

### What is already known on this topic

1.  Venous thromboembolism is a major cause of preventable morbidity and mortality

2.  Independent risk factors have been identified and UK guidelines encourage identification of high risk patients and effective use of preventative measures

3.  There are currently no validated risk prediction algorithms to identify high risk individuals which are suitable for use in primary care

### What this study adds

1.  We have developed and validated a new risk prediction algorithm which identifies patients at high risk of venous thromboembolism with good discrimination and calibration

2.  The algorithm uses simple clinical variables which patients are likely to know or which are routinely recorded in general practice records

3.  The algorithm could be integrated into general practice systems to risk assess patients on medication. It could also be used before hospital admission, long haul flights, or the initiation of medication which might increase the risk of venous thromboembolism.
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